Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas R Latimer

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Melanoma Research|September 5, 2015
Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanomaNicholas R Latimer, Mayur M Amonkar, Ceilidh Stapelkamp, et al.
International Journal of Technology Assessment in Health Care|September 15, 2016
TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALSChris Henshall, Nicholas R Latimer, Lloyd Sansom, et al.
Pharmacoeconomics|April 1, 2024
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology AssessmentsJen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer
Pharmacoeconomics|October 30, 2017
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity AnalysisShijie Ren, Jonathan Minton, Sophie Whyte, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2025
An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence's Single Technology AppraisalsJiyeon Kang, John Cairns, Nicholas R Latimer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient WeightAnthony J Hatswell, Joshua Porter, Dawn Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision MakingTing-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) AddendumAntonia Morga, Nicholas R Latimer, Martin Scott, et al.
Targeted Oncology|December 17, 2016
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate CancerKonstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Melanoma Research|September 5, 2015
Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanomaNicholas R Latimer, Mayur M Amonkar, Ceilidh Stapelkamp, et al.
International Journal of Technology Assessment in Health Care|September 15, 2016
TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALSChris Henshall, Nicholas R Latimer, Lloyd Sansom, et al.
Pharmacoeconomics|April 1, 2024
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology AssessmentsJen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer
Pharmacoeconomics|October 30, 2017
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity AnalysisShijie Ren, Jonathan Minton, Sophie Whyte, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2025
An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence's Single Technology AppraisalsJiyeon Kang, John Cairns, Nicholas R Latimer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient WeightAnthony J Hatswell, Joshua Porter, Dawn Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision MakingTing-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) AddendumAntonia Morga, Nicholas R Latimer, Martin Scott, et al.
Targeted Oncology|December 17, 2016
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate CancerKonstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, et al.
Pageof 5